Worldwide, it is estimated that approximately 334 million people currently suffer from asthma, and 250,000 deaths are attributed to the disease each year. The prevalence of the disease is continuing to grow, and the overall prevalence is estimated to increase by 100 million by 2025. Asthma is a chronic condition with no known cure, but management options are available to improve quality of life and allow patients to live an uninhibited life.
The landscape of asthma has changed considerably after 40 years of inhaled corticosteroid development and nearly 20 years since the first monoclonal antibodies were approved. New members of pharmacological families and more effective drug-delivery devices have been designed but the proportion of uncontrolled patients, unfortunately, remains stable. The most promising treatments now rely on targeted therapies that encourage the improvement of the characterization of patients.
How AdisInsight can help
AdisInsight can help you keep up with the rapid pace of development in immunological and respiratory disorders. It is an integrated database of profiles authored by Springer Nature editors sourced from publicly available information from journals, conferences, trial registries, media releases, company websites, and government filings about pharmaceutical development programs, clinical trial studies, and published individual case safety reports. Information in AdisInsight is updated daily to keep you informed of the latest information impacting your research. Start searching on AdisInsight